Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Kelsie Cowman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Outpatients, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
To assess and compare subsequent hospital admissions within 30 days for patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir.
Methods
We conducted a retrospective review of 3207 high-risk, non-hospitalized adult COVID-19 patients who received a prescription for molnupiravir (n = 209) or nirmatrelvir/ritonavir (n = 2998) at an academic medical centre in New York City from April to December 2022. Variables including age, vaccination status, high-risk conditions and demographic factors were pulled from the electronic medical record. We used multivariable logistic regression to adjust for potential confounding variables.
Results
All-cause 30 day hospitalization was not significantly different between patients who received nirmatrelvir/ritonavir compared with molnupiravir (1.4% versus 1.9%, P value = 0.55). The association between COVID-related hospitalization and medication was also not significant (0.7%versus 0.5%, P value = 0.99). Patients who received molnupiravir were more likely to have more underlying high-risk conditions. After adjusting for potential confounders, the odds of all-cause hospitalizations were not significantly different between patients who received nirmatrelvir/ritonavir compared with molnupiravir (OR = 1.16, 95% CI: 0.4–3.3, P value = 0.79).
Conclusions
These data provide additional evidence to support molnupiravir as a suitable alternative when other COVID-19 antivirals cannot be given.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Network Performance Group, Montefiore Health System, Bronx, NY, USA.
- Department of Pharmacy, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Nursing, Montefiore Medical Center, Bronx, NY, USA.
- Faculty Practice Group, Montefiore Health System, Bronx, NY, USA.
ORCID-Profile: Kelsie Cowman
Zitieren
APA
Cowman, K., Miller, A., Guo, Y., Chang, M. H., McSweeney, T., Bao, H., Simpson, R., Braithwaite, C., Sunu, E., Ros, T., Rodriguez, M., Laboy, E., Bard, L., Alsina, L., Cintron, A., Andrews, E., & Nori, P. (2023). Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad154
Vancouver
Cowman K, Miller A, Guo Y, Chang MH, McSweeney T, Bao H, et al. Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad154
BibTeX
@article{Cowman2023,
author = {Cowman, Kelsie and Miller, Alexander and Guo, Yi and Chang, Mei H and McSweeney, Terrence and Bao, Hongkai and Simpson, Roxanne and Braithwaite, Claire and Sunu, Evans and Ros, Theary and Rodriguez, Maria and Laboy, Eric and Bard, Linda and Alsina, Leslie and Cintron, Angelica and Andrews, Erin and Nori, Priya},
title = {Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad154}
}
EUVIMED